**SUPPLEMENTARY TABLE AND FIGURE**

**SUPPLEMENTARY TABLE S1.** Treatment Exposure by Treatment Arm in the Overall Treated Population and in Chemorefractory and Chemosensitive Subgroups.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Overall population** | | **Chemorefractory subgroup** | | **Chemosensitive subgroup** | |
| **Cabazitaxel (n = 89)** | **Topotecan (n = 88)** | **Cabazitaxel**  **(n = 45)** | **Topotecan**  **(n = 43)** | **Cabazitaxel**  **(n = 44)** | **Topotecan**  **(n = 45)** |
| **Median number of treatment cycles (range)** | 2.0  (1–20) | 4.0  (1–11) | 2.0 (1–20) | 3.0 (1–8) | 2.5 (1–8) | 4.0 (1–11) |
| **Median relative dose intensity,\*% (range)** | 98.9  (61.1–103.0) | 91.8  (57.6–104.8) | 98.9  (72.5–101.7) | 93.2  (59.2–104.8) | 98.6  (61.1–103.0) | 86.8  (57.6–101.6) |
| **Treatment discontinuation, n (%)** | 88 (98.9) | 87 (98.9) | 44 (97.8) | 43 (100) | 44 (100) | 44 (97.8) |
| Disease progression | 70 (78.7) | 50 (56.8) | 38 (84.4) | 30 (69.8) | 32 (72.7) | 20 (44.4) |
| Adverse event | 14 (15.7) | 24 (27.3) | 4 (8.9) | 8 (18.6) | 10 (22.7) | 16 (35.6) |
| Patient request | 1 (1.1) | 5 (5.7) | 1 (2.2) | 2 (4.7) | 0 | 3 (6.7) |
| Other | 3 (3.4) | 8 (9.1) | 1 (2.2) | 3 (7.0) | 2 (4.5) | 5 (11.1) |

\*Relative dose intensity is defined as the ratio of the actual dose intensity (the cumulative dose divided by the number of weeks on study) to the planned dose intensity.

**SUPPLEMENTARY FIGURE S1. CONSORT diagram**

